We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Fractyl Health Inc (GUTS) USD0.00001

Sell:$4.10 Buy:$4.79 Change: $0.03 (0.63%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:$4.10
Buy:$4.79
Change: $0.03 (0.63%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:$4.10
Buy:$4.79
Change: $0.03 (0.63%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity. The Revita DMR System (Revita), the Company’s lead product candidate, is an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The Revita system is designed to enable durable and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. The Company is involved in enrolling is pivotal Revitalize-1 study in patients with inadequately controlled T2D. It is also developing Rejuva, a locally administered, adeno-associated virus (AAV), delivered pancreatic gene therapy (PGTx), platform. Rejuva is designed to enable long-term remission of T2D and obesity.

Contact details

Address:
3 Van De Graaff Drive, Suite 200
BURLINGTON
01803
United States
Telephone:
+1 (781) 9028800
Website:
https://www.fractyl.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GUTS
ISIN:
US35168W1036
Market cap:
$215.54 million
Shares in issue:
47.90 million
Sector:
Health Care Equipment
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Jay Caplan
    President, Co-Founder, Chief Product Officer
  • Harith Rajagopalan
    Chief Executive Officer, Co-Founder, Director
  • Lisa Davidson
    Chief Financial Officer, Treasurer
  • Timothy Kieffer
    Chief Scientific Officer
  • Sarah Toomey
    General Counsel, Corporate Secretary
  • Helmut Giersiefen
    Head of Business Development
  • Adrian Kimber
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.